Predictive Oncology (POAI) Stock Price, News & Analysis

Company Overview

Predictive Oncology, Inc. is a biotechnology company that leverages artificial intelligence and digital biology to support drug discovery and development in oncology. Its core business revolves around the application of machine learning algorithms to high-content cellular imaging, multi-omic profiling, and clinical response data. By integrating these diverse data streams, the company aims to generate predictive models that forecast the efficacy and toxicity of candidate therapeutics, thereby accelerating preclinical decision-making and reducing development timelines.

The company’s primary offerings include its Phenomics platform, which combines automated microscopy with advanced image analysis to capture subtle phenotypic changes in cancer cells. This platform is complemented by proprietary data integration tools that correlate cellular phenotypes with genetic and molecular profiles. Predictive Oncology also provides custom assay development and contract research services to pharmaceutical and biotech partners seeking to validate drug mechanisms, optimize dosing regimens, or identify novel targets in oncology and related therapeutic areas.

Headquartered in St. James, New York, Predictive Oncology serves a global customer base that includes large pharmaceutical companies, emerging biotechs, and academic research institutions. The company began trading on the Nasdaq Capital Market under the ticker POAI in December 2020. Its leadership team brings together expertise in computational biology, oncology research, and data science, positioning Predictive Oncology at the intersection of cutting-edge technology and translational cancer research.

Key Stats

• Today's Range: $0.91 to $0.99
• 50-Day Range: $0.73 to $1.02
• 52-Week Range: $0.55 to $3.06
• Volume: 118,402 shs
• Average Volume: 1.76 million shs
• Market Capitalization: $10.93 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Predictive Oncology Stock Analysis - MarketRank™

Predictive Oncology scored higher than 26% of companies evaluated by MarketBeat, and ranked 856th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Predictive Oncology.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Predictive Oncology are expected to grow in the coming year, from ($2.08) to ($0.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Predictive Oncology is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Predictive Oncology is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.03% of the float of Predictive Oncology has been sold short.

Short Interest Ratio / Days to Cover

Predictive Oncology has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Predictive Oncology has recently decreased by 54.38%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Predictive Oncology does not currently pay a dividend.

Dividend Growth

Predictive Oncology does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.03% of the float of Predictive Oncology has been sold short.

Short Interest Ratio / Days to Cover

Predictive Oncology has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Predictive Oncology has recently decreased by 54.38%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.45

News Sentiment

Predictive Oncology has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Predictive Oncology this week, compared to 1 article on an average week.

Search Interest

5 people have searched for POAI on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Predictive Oncology insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.44% of the stock of Predictive Oncology is held by insiders.

Percentage Held by Institutions

Only 9.04% of the stock of Predictive Oncology is held by institutions.

POAI Stock Analysis - Frequently Asked Questions

How have POAI shares performed this year?

Predictive Oncology's stock was trading at $0.82 at the beginning of 2025. Since then, POAI shares have increased by 13.4% and is now trading at $0.93.

How were Predictive Oncology's earnings last quarter?

Predictive Oncology Inc. (NASDAQ:POAI) posted its quarterly earnings results on Wednesday, August, 13th. The medical instruments supplier reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.13. The medical instruments supplier had revenue of $0 million for the quarter, compared to analyst estimates of $1.50 million. Predictive Oncology had a negative net margin of 587.31% and a negative trailing twelve-month return on equity of 722.01%.

When did Predictive Oncology's stock split?

Predictive Oncology's stock reverse split on the morning of Monday, April 24th 2023.The 1-20 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Predictive Oncology?

Shares of POAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Predictive Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Predictive Oncology investors own include Ford Motor (F), Wells Fargo & Company (WFC), Zomedica (ZOM), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Bank of America (BAC) and Wayfair (W).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 9/16/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:POAI
• CIK: 1446159
• Web: www.precisiontherapeutics.com
• Phone: (651) 389-4800
• Fax: N/A
• Employees: 30
• Year Founded: 2002

Profitability

• EPS (Trailing Twelve Months): ($3.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.66 million
• Net Margins: -587.31%
• Pretax Margin: -546.76%
• Return on Equity: -722.01%
• Return on Assets: -167.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.32
• Quick Ratio: 0.31

Sales & Book Value

• Annual Sales: $1.62 million
• Price / Sales: 6.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.03) per share
• Price / Book: -31.10

Miscellaneous

• Outstanding Shares: 10,890,000
• Free Float: 10,518,000
• Market Cap: $10.16 million
• Optionable: Not Optionable
• Beta: 1.37